Our long term goal is to establish an NCI designated cancer center for West Virginia (WV) and the surrounding Appalachian region. West Virginia University (WVU) is the flagship university and medical center in the state with no cancer centers in WV currently having NCI designation. Our Phase I-II CoBREs for Signal Transduction and Cancer (P20) were designed to support basic research development as a .critical component of successfully competing for a Cancer Center Support Grant (CCSG) and coincident NCI designation for the WVU Mary Babb Randolph Cancer Center (MBRCC).
The specific aims of our Phase I and Phase II CoBREs evolved from an initial focus on junior investigators with a primary goal of nurturing career development and independent funding (Phase I) to a combination of continued support of junior investigators with establishment of a critical mass in targeted thematic areas during Phase II. In addition, the establishment and strengthening of essential core facilities was supported during Phases I-II and the final stage of this critical core and infrastructure support defines the focus of our Phase III (PSO) Transition Award. Established scientific thematic areas in the MBRCC include Programs focused on the Molecular Mechanisms of EMT and Metastasis, Breast Cancer, Hematopoietic Malignancies and Transplantation, and Translational Tobacco Reduction Research. These Programs provide a structured atmosphere for collaboration and mentoring for the MBRCC members and the platform in which to shape multi-investigator and programmatic grant applications. Relevant to this Transition Award application, projects throughout all of these Programs are supported by the Cores for which support is requested: Flow Cytometry, Microscope Imaging, Animal Models and Imaging, Protein, Biostatistics and Bioinformatics, and Biospecimen Processing.
The specific aims of this Phase III Transition Award include (1) support of state-of-the-art technology and expertise in sustainable core facilities that emphasize accessibility and training in which we nurture career development of investigators undertaking cancer related research and (2) enhanced collaboration in the MBRCC, WVU and the state to maximize the impact of CoBRE investment to ensure maximum access to technology required for high quality, extramurally funded research. Emphasis has been placed on strategies to support collaboration, sustainability, and an avoidance of redundant investment to yield the greatest impact of this award on continued growth of the MBRCC, in part, through availability of outstanding core facility support. Collectively, these efforts support our long-term goal of NCI designation.
WV is characterized by unique health disparities which drive the design of our scientific Programs of focus. CoBRE support has allowed training of scientists, core facility development, and programmatic growth to underpin research that directly contributes to impacting positively on the health of WV residents with diverse malignancies. These successes contribute to our capacity to gain NCI designation which will further strengthen our capacity for research, training and top notch clinical care for residents of the state.
|Famodu, Oluremi A; Barr, Makenzie L; Colby, Sarah E et al. (2018) Neck Circumference Positively Relates to Cardiovascular Risk Factors in College Students. Int J Environ Res Public Health 15:|
|MacFawn, Ian; Wilson, Hannah; Selth, Luke A et al. (2018) Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. Mol Immunol 105:137-149|
|Li, Bingyun; Webster, Thomas J (2018) Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J Orthop Res 36:22-32|
|Rodgers, H M; Huffman, V J; Voronina, V A et al. (2018) The role of the Rx homeobox gene in retinal progenitor proliferation and cell fate specification. Mech Dev 151:18-29|
|Nair, Rajesh R; Geldenhuys, Werner J; Piktel, Debbie et al. (2018) Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia. Bioorg Med Chem Lett 28:1937-1942|
|Shah, Neal; Mohammad, Afroz S; Saralkar, Pushkar et al. (2018) Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res 132:47-68|
|Bland, Cassidy L; Byrne-Hoffman, Christina N; Fernandez, Audry et al. (2018) Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. FEBS J 285:1033-1050|
|Mohammad, Afroz S; Griffith, Jessica I; Adkins, Chris E et al. (2018) Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res 35:31|
|Zhang, Shichao; Xing, Malcolm M Q; Li, Bingyun (2018) Capsule Integrated Polypeptide Multilayer Films for Effective pH-Responsive Multiple Drug Co-Delivery. ACS Appl Mater Interfaces :|
|Shepherd, Danielle L; Hathaway, Quincy A; Nichols, Cody E et al. (2018) Mitochondrial proteome disruption in the diabetic heart through targeted epigenetic regulation at the mitochondrial heat shock protein 70 (mtHsp70) nuclear locus. J Mol Cell Cardiol 119:104-115|
Showing the most recent 10 out of 158 publications